CAS 395639-53-9|Aselizumab
Introduction：Basic information about CAS 395639-53-9|Aselizumab, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Aselizumab | ||
|---|---|---|---|
| CAS Number | 395639-53-9 | Molecular Weight | / |
| Density | / | Boiling Point | / |
| Molecular Formula | / | Melting Point | / |
| MSDS | / | Flash Point | / |
Names
| Name | Aselizumab |
|---|
Aselizumab BiologicalActivity
| Description | Aselizumab (HuDreg-55) is an humanized IgG4 mAb against L-selectin. However, L-selectin (CD62L) is a cell adhesion molecule expressed on circulating neutrophils. It regulates migrating cells to chemotaxis towards the site of injury. Aselizumab may be account for a high rate of infections and leucopenia after truma[1][2]. |
|---|---|
| Related Catalog | Signaling Pathways >>Others >>OthersResearch Areas >>Inflammation/Immunology |
| Target | L-selectin[1][2] |
| In Vitro | Aselizumab 可与人鼠单克隆 HuDreg-55 轻链二硫化形成二聚体[1]。 Aselizumab (5-500 ng/mL; 25 分钟) 在冷冻淋巴结切片中阻断人淋巴细胞对高内皮小静脉的 L-选择素依赖性粘附[3]。 |
| In Vivo | Aselizumab (10 mg/kg; 静脉注射; 单次剂量) 在恒河猴中显示出 12.0 天的最终消除半衰期[3]。 |
| References | [1]. Seekamp A, et al. The effect of anti-L-selectin (aselizumab) in multiple traumatized patients--results of a phase II clinical trial. Crit Care Med. 2004 Oct;32(10):2021-8. [2]. Rahman I, et al. L-selectin regulates human neutrophil transendothelial migration. J Cell Sci. 2021 Feb 8;134(3):jcs250340. [3]. Co MS, et al. Properties and pharmacokinetics of two humanized antibodies specific for L-selectin. Immunotechnology. 1999 Mar;4(3-4):253-66. |
Chemical & Physical Properties
| No Any Chemical & Physical Properties |
